Pathologic Diagnosis and Reporting of Barrett’s Esophagus

Diagnostic Criteria

• Barrett’s esophagus is diagnosed when metaplastic columnar epithelium is identified in biopsies taken from an endoscopically visible columnar‑lined esophagus that extends at least 1 cm above the gastro‑esophageal junction, and the diagnosis requires synthesis of both endoscopic and histologic findings. [1][2]

• A definitive pathologic diagnosis is achieved when columnar mucosa is observed adjacent to native esophageal structures (submucosal glands, gland ducts, multilayered epithelium, or squamous islands). [2][3]

• Native esophageal structures are present in only 10–15 % of biopsy samples, so definitive confirmation of esophageal origin is possible in fewer than one‑in‑six cases. [2][3]

Types of Metaplasia and Cancer Risk

• Barrett’s with intestinal metaplasia – characterized by specialized columnar epithelium containing acid‑mucin goblet cells (most often incomplete type II/III; complete type I may also occur). [2][3]

• The annual incidence of high‑grade dysplasia or adenocarcinoma in patients with intestinal metaplasia is ≈0.38 % versus ≈0.07 % in those without goblet cells. [2][3]

• Barrett’s with gastric (cardiac/fundic) metaplasia only – contains cardiac‑type or fundic‑type epithelium without goblet cells. [2][3]

• The British Society of Gastroenterology recognizes gastric‑type metaplasia as Barrett’s esophagus, although it carries a lower malignant potential than intestinal metaplasia. 2

Distinguishing Barrett’s from Gastric Cardia Metaplasia

• Morphologic differentiation between true Barrett’s and intestinal metaplasia of the gastric cardia is difficult in most cases, except when native esophageal structures are identified. [2][3]

• Cytokeratin 7 and Cytokeratin 20 immunostaining patterns have not proven sufficiently reproducible for routine clinical use. 2

• Consequently, the distinction must be made endoscopically by accurately labeling the biopsy site relative to endoscopic landmarks (proximal gastric folds, distance from incisors, Prague C & M classification). [2][3]

Required Pathology Reporting Elements

• The pathology report must document:

Reporting Categories

• Based on histologic findings, the report should use one of three standardized categories:

Integration with Endoscopic Findings

• Histopathologic diagnosis must be integrated with endoscopic observations to reach an accurate clinical diagnosis. [2][3]

• Endoscopists should label each biopsy site using recognized landmarks (proximal gastric folds, distance from incisors, Prague C & M classification) to ensure proper correlation with pathology. [1][2]

Guideline Society Positions and Controversies

• The American Gastroenterological Association defines Barrett’s esophagus as requiring intestinal metaplasia (presence of goblet cells). 4

• The British Society of Gastroenterology accepts Barrett’s esophagus even when only gastric‑type metaplasia is present. 2

• The 2024 NICE guidelines acknowledge that individuals with intestinal metaplasia have a higher risk of progression to cancer than those with gastric‑type epithelium alone. 5

Classification and Diagnosis of Barrett's Esophagus

Endoscopic Classification

• The American Gastroenterological Association recommends using the Prague C&M criteria for documenting Barrett's extent, which includes the circumferential extent (C) and maximum extent (M) of columnar-lined epithelium above the gastroesophageal junction 6, 7
• A minimum diagnostic threshold of at least 1 cm of columnar epithelium must be clearly visible above the gastroesophageal junction for an endoscopic diagnosis, as stated by the British Society of Gastroenterology 8, 9, 10
• Long-segment Barrett's esophagus (LSBO) is typically defined as ≥3 cm of columnar-lined epithelium, while short-segment Barrett's esophagus (SSBO) is defined as <3 cm, with longer segments carrying higher cancer risk 11, 12

Histopathological Classification

• The British Society of Gastroenterology recognizes Barrett's esophagus with gastric metaplasia only, which contains gastric fundal-type or junctional-type epithelium without goblet cells, although it carries lower cancer risk 8, 9, 13
• Barrett's esophagus with intestinal metaplasia contains specialized columnar epithelium with acid mucin-containing goblet cells and is considered the most biologically unstable type with the highest cancer risk, with an annual incidence of high-grade dysplasia/cancer of 0.38% 14, 13

Dysplasia Classification

• The American College of Gastroenterology recommends classifying dysplasia as non-dysplastic, indefinite for dysplasia, low-grade dysplasia, high-grade dysplasia, or intramucosal carcinoma, with high-grade dysplasia involving neoplastic changes throughout the full thickness of the epithelium 6, 14, 11
• Dysplasia diagnosis has significant interobserver variability, particularly distinguishing indefinite from low-grade dysplasia, and all dysplasia diagnoses must be confirmed by an expert gastrointestinal pathologist before treatment decisions, as stated by the American Gastroenterological Association 6, 7

Diagnostic Requirements

• A definitive Barrett's diagnosis requires synthesis of both endoscopic and histopathological findings, including ≥1 cm columnar epithelium above the gastroesophageal junction using Prague criteria and columnar metaplasia on four-quadrant biopsies every 2 cm, as recommended by the British Society of Gastroenterology 8, 9, 13

Diagnostic Confirmation and Management of Barrett’s Esophagus at the Gastro‑Oesophageal Junction

1. Diagnostic Confirmation

• True Barrett’s esophagus requires endoscopic demonstration of columnar epithelium extending ≥ 1 cm above the gastro‑oesophageal junction (GOJ) using the Prague C & M classification, followed by systematic four‑quadrant biopsies every 2 cm. [British Society of Gastroenterology, 2014] [15]
• The proximal limit of longitudinal gastric folds with minimal air insufflation (reliability coefficient 0.88) is the most reliable landmark for identifying the GOJ. [British Society of Gastroenterology, 2014] [15]
• Presence of goblet cells alone does not confirm Barrett’s; histology must be correlated with endoscopic columnar length ≥ 1 cm. [British Society of Gastroenterology, 2014] [15]

2. Initial Risk Stratification

• Long‑segment Barrett’s (≥ 3 cm) carries a higher risk of progression to adenocarcinoma and therefore warrants more intensive surveillance. [British Society of Gastroenterology, 2014] [16]17
• Short‑segment Barrett’s (< 3 cm) still confers a significant cancer risk, albeit lower than long‑segment disease. [British Society of Gastroenterology, 2014] [16]17

3. Acid‑Suppression Therapy

• High‑dose proton‑pump inhibitor (PPI) therapy (e.g., omeprazole 20–40 mg daily) should be initiated immediately to control reflux and reduce progression risk. [British Society of Gastroenterology, 2002] [18]
• PPI therapy can induce regression of low‑grade dysplasia but may also produce regenerative inflammatory atypia that mimics high‑grade dysplasia; objective endoscopic assessment is required. [British Society of Gastroenterology, 2002] [18]

4. Surveillance Protocol for Non‑Dysplastic Barrett’s

• Barrett’s segment ≥ 3 cm: endoscopy every 2–3 years with four‑quadrant biopsies every 2 cm (Seattle protocol).** [British Society of Gastroenterology, 2014] [16]17
• Barrett’s segment < 3 cm: endoscopy every 3–5 years with four‑quadrant biopsies every 2 cm.** [British Society of Gastroenterology, 2014] [16]17
• Barrett’s with gastric (cardiac) metaplasia only (no goblet cells): surveillance may be less intensive, although British guidelines still classify this as Barrett’s.** [British Society of Gastroenterology, 2014] [15]

5. Dysplasia Detection and Management

• All dysplasia diagnoses must be confirmed by a second expert GI pathologist before therapeutic decisions are made. [British Society of Gastroenterology, 2014; American Gastroenterological Association, 2016] [15]19

Low‑Grade Dysplasia (LGD)

• Repeat endoscopy after intensifying PPI therapy to exclude inflammatory atypia. [American Gastroenterological Association, 2016] [19]
• If LGD persists on repeat endoscopy with expert pathology confirmation, discuss endoscopic eradication therapy (radiofrequency ablation) versus a 6‑month surveillance interval. [American Gastroenterological Association, 2016] [19]
• Visible lesions must be resected endoscopically to allow accurate histologic grading. [American Gastroenterological Association, 2016] [19]
• Surveillance after choosing observation: endoscopy every 6 months for two examinations, then annually.** [American Gastroenterological Association, 2016] [19]

High‑Grade Dysplasia (HGD)

• Up to 40 % of HGD specimens harbor occult adenocarcinoma; urgent repeat endoscopy with extensive biopsies is required. [British Society of Gastroenterology, 2002; British Society of Gastroenterology, 2002] [18]20
• Refer immediately to an expert endoscopist for endoscopic resection of any visible lesion and consider adjunctive ablation therapy. [British Society of Gastroenterology, 2014; American Gastroenterological Association, 2016] [15]19
• Multidisciplinary team discussion is mandatory before definitive treatment. [British Society of Gastroenterology, 2014] [15]

6. Patient Counseling Essentials

• Explain the annual cancer risk (~0.38 % per year) associated with intestinal metaplasia. [British Society of Gastroenterology, 2014] [16]
• Emphasize the need for lifelong high‑dose PPI therapy and lifestyle measures to control reflux. [British Society of Gastroenterology, 2014] [16]
• Clarify that surveillance aims for early cancer detection, which improves survival despite the lack of randomized trial data. [British Society of Gastroenterology, 2014] [15]
• Outline therapeutic options if dysplasia develops (endoscopic eradication vs. surgical resection). [British Society of Gastroenterology, 2014] [16]
• Record family history of Barrett’s or esophageal adenocarcinoma as part of risk assessment. [British Society of Gastroenterology, 2014] [16]

7. Common Pitfalls to Avoid

• Do not diagnose Barrett’s solely on histology without endoscopic confirmation of ≥ 1 cm columnar epithelium. [British Society of Gastroenterology, 2014] [15]
• Do not initiate surveillance for irregular Z‑lines (< 1 cm) even if intestinal metaplasia is present on biopsy. [British Society of Gastroenterology, 2014] [15]
• Do not rely on symptom assessment alone to gauge reflux control; objective endoscopic or pH testing is required. [British Society of Gastroenterology, 2014] [18]
• Do not accept a dysplasia diagnosis without confirmation by an expert GI pathologist because of high inter‑observer variability. [British Society of Gastroenterology, 2014; American Gastroenterological Association, 2016] [15]19
• Do not perform ablative therapy before endoscopic resection of visible lesions, as this precludes accurate histologic grading. [American Gastroenterological Association, 2016] [19]

8. Post‑Eradication Surveillance

• After complete endoscopic eradication of intestinal metaplasia, schedule surveillance endoscopy at 1 year, 2 years, and then every 3 years. [American Gastroenterological Association, 2016] [19]
• Continue four‑quadrant biopsies every 2 cm during surveillance to detect recurrent intestinal metaplasia. [American Gastroenterological Association, 2016] [19]
• Maintain lifelong high‑dose PPI therapy to suppress reflux and reduce recurrence risk. [American Gastroenterological Association, 2016] [19]

Diagnostic Criteria and Management of Barrett’s Esophagus

1. Diagnostic Requirements – Two‑Step Process

• Endoscopic criterion: Columnar epithelium must extend ≥ 1 cm above the gastro‑esophageal junction (GOJ), measured with the Prague C & M classification system. The GOJ is identified as the proximal limit of longitudinal gastric folds with minimal air insufflation (reliability coefficient 0.88). [American Gastroenterological Association] 21

• Irregular Z‑lines (tongues of columnar epithelium < 1 cm) must not be diagnosed as Barrett’s esophagus, even if intestinal metaplasia is found on biopsy. [American Gastroenterological Association] 21

• Histologic confirmation: Diagnosis requires metaplastic columnar epithelium; the presence of intestinal metaplasia (goblet cells) confers the highest cancer risk. [American Gastroenterological Association] [22][23]

2. Histologic Subtypes and Cancer Risk

3. Definitive Esophageal Origin

• Definitive confirmation of esophageal columnar metaplasia is possible only when columnar mucosa is adjacent to native esophageal structures (submucosal glands, gland ducts, multilayered epithelium, or squamous islands). [British Society of Gastroenterology] 21

• Such native structures are identified in 10–15 % of biopsies, meaning definitive confirmation occurs in fewer than one‑in‑six cases. [British Society of Gastroenterology] 21

• In the majority of cases lacking native structures, the diagnosis relies on endoscopic documentation that the biopsy was taken from columnar epithelium ≥ 1 cm above the GOJ. [British Society of Gastroenterology] 21

4. Common Pitfalls to Avoid

• Do not label columnar epithelium extending < 1 cm above the GOJ (irregular Z‑line) as Barrett’s, even with intestinal metaplasia. [British Society of Gastroenterology] 21

• Do not diagnose Barrett’s when biopsies are taken from the GOJ or gastric cardia without clear endoscopic evidence that the tissue originates from esophageal columnar lining. [British Society of Gastroenterology] 21 & [American Gastroenterological Association] 22

• Do not use the term “Barrett’s esophagus” for patients with only cardiac‑type epithelium lacking goblet cells according to American guidelines (British guidelines differ). [American Gastroenterological Association] [22][23]

5. Practical Diagnostic Algorithm

• Goblet cells present → Barrett’s with intestinal metaplasia → surveillance every 2–5 years depending on segment length. [British Society of Gastroenterology] 21
• Only cardiac/fundic epithelium → Follow British guidance (optional surveillance) or American guidance (no surveillance). [American Gastroenterological Association]** [22][23] [British Society of Gastroenterology]** 25
• Native esophageal structures identified → Definitive Barrett’s diagnosis. [British Society of Gastroenterology] 21